Erythrodermic Psoriasis Managed with Risankizumab.

IF 0.9 Q4 DERMATOLOGY
Case Reports in Dermatology Pub Date : 2022-08-19 eCollection Date: 2022-05-01 DOI:10.1159/000525774
Abdulmajeed Alajlan, Abdulaziz Madani, Tala Ammar Qadoumi, Alhanouf Aljaloud, Mohammed Alessa
{"title":"Erythrodermic Psoriasis Managed with Risankizumab.","authors":"Abdulmajeed Alajlan,&nbsp;Abdulaziz Madani,&nbsp;Tala Ammar Qadoumi,&nbsp;Alhanouf Aljaloud,&nbsp;Mohammed Alessa","doi":"10.1159/000525774","DOIUrl":null,"url":null,"abstract":"<p><p>Erythrodermic psoriasis (EP) is a severe, often refractory, variant of psoriasis. Due to the high morbidity and mortality rate associated with EP and other causes of erythroderma, they are often classified as dermatologic emergencies. EP is usually a therapeutic challenge, where topical and conventional systemic therapies have yielded a less than satisfactory result in several patients. Furthermore, there are a limited number of studies evaluating other therapeutic modalities, such as biologic agents, with no clear treatment guidelines. In this case report, we present a patient who was diagnosed as a case of EP and showed an impressive response to risankizumab.</p>","PeriodicalId":9619,"journal":{"name":"Case Reports in Dermatology","volume":null,"pages":null},"PeriodicalIF":0.9000,"publicationDate":"2022-08-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/7b/a6/cde-0014-0219.PMC9459644.pdf","citationCount":"3","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Case Reports in Dermatology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1159/000525774","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/5/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"DERMATOLOGY","Score":null,"Total":0}
引用次数: 3

Abstract

Erythrodermic psoriasis (EP) is a severe, often refractory, variant of psoriasis. Due to the high morbidity and mortality rate associated with EP and other causes of erythroderma, they are often classified as dermatologic emergencies. EP is usually a therapeutic challenge, where topical and conventional systemic therapies have yielded a less than satisfactory result in several patients. Furthermore, there are a limited number of studies evaluating other therapeutic modalities, such as biologic agents, with no clear treatment guidelines. In this case report, we present a patient who was diagnosed as a case of EP and showed an impressive response to risankizumab.

Abstract Image

Abstract Image

Abstract Image

瑞尚单抗治疗红皮病性银屑病。
红皮病型牛皮癣(EP)是一种严重的、通常难治性的牛皮癣变型。由于EP和其他原因引起的红皮病的高发病率和死亡率,它们通常被归类为皮肤急症。EP通常是一种治疗挑战,局部和常规全身治疗在一些患者中产生了不太令人满意的结果。此外,评估其他治疗方式(如生物制剂)的研究数量有限,没有明确的治疗指南。在这个病例报告中,我们提出了一个被诊断为EP病例的患者,并对瑞尚单抗显示出令人印象深刻的反应。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
1.60
自引率
0.00%
发文量
57
审稿时长
9 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信